8 things you need to know about eCTDs in China
At the end of 2021, China implemented electronic Common Technical Document (eCTD) submissions to accelerate the review and approval of new pharmaceuticals. eCTDs ultimately benefit pharmaceutical and biotech companies by expediting review times, which means faster approvals and a faster time to market. For the regulatory authorities, eCTDs enable more efficient review processes. Although this is a huge step forward for standardization in the Asia Pacific, there are several important things you need to know before you submit your dossier electronically.
Here are eight things you need to know.
Related Insights
Article
How a joined-up development strategy pays off for early-stage biotechs
May 19, 2021
Blog
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Video
Overcoming asset transfer challenges during a merger and acquisition (M&A)
Oct 20, 2021
Playbook
Early-phase development strategies for navigating regulatory complexity in the EU
Apr 29, 2024
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Playbook
What emerging trends in the FDA’s most coveted designations might tell us
Feb 8, 2024
Podcast
RBQM Podcast Series | Episode 3: Staying within the Guardrails: How to Push the Boundaries in a Highly Regulated Industry
Jun 16, 2022
Blog
Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions
May 16, 2022
Blog
How can ECAs be used to accelerate the development of better medicines?
Nov 25, 2024
Article
New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle
May 10, 2022
Related Insights
Article
How a joined-up development strategy pays off for early-stage biotechs
May 19, 2021
Blog
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Video
Overcoming asset transfer challenges during a merger and acquisition (M&A)
Oct 20, 2021
Playbook
Early-phase development strategies for navigating regulatory complexity in the EU
Apr 29, 2024
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Playbook
What emerging trends in the FDA’s most coveted designations might tell us
Feb 8, 2024
Podcast
RBQM Podcast Series | Episode 3: Staying within the Guardrails: How to Push the Boundaries in a Highly Regulated Industry
Jun 16, 2022
Blog
Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions
May 16, 2022
Blog
How can ECAs be used to accelerate the development of better medicines?
Nov 25, 2024
Article
New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle
May 10, 2022